Tarsus Pharmaceuticals, Inc. TARS Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s restricted cash?
- Tarsus Pharmaceuticals, Inc. (TARS) reported restricted cash of $0 in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s restricted cash changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s restricted cash decreased by 100.0% year-over-year, from $2.56M to $0.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s restricted cash?
- Over 4 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s restricted cash has grown at a 130.0% compound annual growth rate (CAGR), from $20K to $560K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.